Novartis execs highlight progress of slimmer pipeline after Sandoz spinoff
Novartis executives on Tuesday crystallized their ongoing R&D strategy shift in the wake of the Sandoz spinoff, with CEO Vas Narasimhan and others outlining how the company aims to be more efficient and its decisions streamlined.
Gone are the days of “Wild Card” drugs, replaced by a slimmed-down pipeline with much more “alignment” across departments about which diseases to tackle. It marks a shift from the past, the CEO said, about making sure Novartis is “very, very clear” on the diseases it wants to treat and drugs it wants to pursue.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.